Pfizer's rebound faces pipeline setbacks and patent cliff risks
- The non-COVID business continues to grow, driving a total revenue guidance raise in Q2 2026.
- COVID-19 product guidance was cut again, falling from $5 billion to $4 billion for 2026.
- A $4.3 billion impairment charge for pipeline assets highlights drug development risks.
- The Section 232 tariff threat was resolved, removing a major margin risk.
- The 2026 through 2030 patent cliff remains the central threat to the stock.
A strong core fighting pipeline and patent issues
Pfizer’s post-COVID transition is a story of two businesses. The core non-COVID portfolio is outperforming expectations, growing 5% operationally in Q2 2026 and leading to a guidance raise. Cancer drugs are a bright spot, with Padcev winning a major label expansion in bladder cancer.
However, the rest of the business is struggling to find a bottom. COVID-19 revenue guidance was cut again to $4 billion. The acquired pipeline also took a hit, as Pfizer recorded a $4.3 billion impairment charge after clinical setbacks for its SV asset in lung cancer and Oxbryta.
The biggest long-term test remains the 2026 through 2030 patent cliff. Pfizer resolved the Section 232 tariff risk, which helps margins, and expanded its cost savings target to $9.7 billion by 2029. Yet cost cuts cannot replace lost blockbusters.
Finn’s view is cautious. Valuation is fair, but growth and performance scores remain weak. To win over investors, Pfizer needs its remaining Seagen assets and obesity pipeline to deliver before patent losses accelerate.
Patents turn science into cash
Pfizer makes money by discovering, developing, making, and selling medicines and vaccines. The best years for a drug are usually when patents protect it from cheap copycat drugs. After patents expire, generic or biosimilar rivals can push sales and prices down fast.
The company spends heavily on research and development. It also buys or licenses drugs from other companies when it wants to add growth faster than its own labs can provide it. Seagen is the current example, giving Pfizer a larger cancer drug base.
The model breaks when old blockbusters fade before new ones are ready. That is Pfizer’s core test now. Management is aggressively executing cost realignment programs, targeting $9.7 billion in total net savings through 2029 to improve margins and support reinvestment.
The drugs that matter most
Vyndaqel family and Vyndamax
These heart drugs are key revenue drivers. An April 2026 legal settlement extended Vyndamax patent exclusivity to 2031, which gives Pfizer more cash flow visibility.
Eliquis
Eliquis is a major blood thinner sold with a partner. It faces Medicare price negotiation pressure under the IRA, with a new Medicare price required from January 1, 2026.
Padcev and Seagen oncology assets
Cancer is becoming Pfizer’s main growth engine. Padcev recently expanded its approved indication to include muscle invasive bladder cancer.
Prevnar family
Prevnar vaccines are part of Pfizer’s broad vaccine base. They help diversify the business beyond cancer and specialty drugs.
Ibrance and Xtandi
These are important cancer products, but the older portfolio faces pricing and exclusivity pressure. Ibrance has also been cited as affected by IRA-related manufacturer discounts.
Comirnaty and Paxlovid
The COVID-19 vaccine and antiviral still matter, but demand is falling from pandemic highs. The company cut 2026 guidance for these products to $4 billion.
Berobenatide
This obesity drug is a long-term option. Pfizer is aggressively advancing the asset with 10 Phase 3 trials planned for 2026, targeting first approvals in 2028.
One segment, two big markets
Pfizer reports Biopharma as its sole reportable segment. The mix shown uses 2025 geographic revenue: U.S. revenue was $37.1 billion and International revenue was $25.5 billion, out of total revenue of $62.6 billion.
What could still break
Patent cliff hits faster than launches grow
High impact · High oddsPfizer expects a significant revenue reduction from patent and regulatory exclusivity losses in 2026 through 2030. Vyndamax protection to 2031 helps, but it does not protect the whole company. If new products fail to scale, revenue can shrink even if the science looks promising.
Drug pricing pressure lowers net prices
High impact · High oddsThe IRA is already hitting net prices through Medicare changes and manufacturer discounts. Eliquis is among the first drugs subject to Medicare price negotiation. The OBBBA could add more pressure by reducing federal healthcare spending and increasing price controls.
Pipeline execution falters
High impact · Medium oddsDrug development is risky, and Pfizer needs wins to replace older drugs. The recent $4.3 billion impairment charge for SV and Oxbryta shows that acquired assets are not immune to clinical setbacks. A few more weak readouts could make the patent cliff harder to offset.
COVID-19 revenues fall below expectations
Medium impact · Medium oddsThe COVID-19 franchise is finding a lower floor than previously expected. Guidance was cut to $4 billion in Q2 2026. Further structural declines would force the core business to work harder to offset the drag.
In one breath
Why is Pfizer stock still under pressure?
Despite strong non-COVID growth, investors are worried about the 2026 through 2030 patent cliff. Pricing rules, pipeline setbacks, and fading COVID-19 demand also weigh on the stock.
What is the biggest bull case for Pfizer?
The bull case is that Pfizer’s post-COVID rebuild is working. Non-COVID revenue grew 5% operationally in Q2 2026, cost cuts were expanded to $9.7 billion, and the Section 232 tariff threat was resolved.
What is Seagen doing for Pfizer?
Seagen gives Pfizer a stronger cancer drug portfolio. Its assets are growing fast, and Padcev recently won a major label expansion, making the deal a clear growth driver.
What should investors watch next?
Watch 2026 pipeline readouts, the start of berobenatide Phase 3 obesity studies, and Seagen growth. These will show whether Pfizer can offset its patent losses.
